It was obvious that the combination therapy showed a superior antitumor effect over the anti-PD-1 antibody did in both tumor growth and tumor weights (CGA + Anti-PD-1 vs. NS + Anti-PD-1, p < 0.05, p < 0.05 for MC38; p < 0.01, p < 0.05 for 4T1). Here, PDCD1 is linked to neoplasm.